Hepatitis B surface antigen loss: Not all that we hoped it would be

Hepatology

Volumn 64, Issue 2, 2016, Pages 328-329

  Nathanson, Michael H ^a   Terrault, Norah ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ANTIVIRAL THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CHRONIC HEPATITIS B; COHORT ANALYSIS; DISEASE SURVEILLANCE; ELASTOGRAPHY; HEPATITIS B VIRUS; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; RISK REDUCTION; SCREENING TEST; VIRAL CLEARANCE;

EID: 84978976118     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28640     Document Type: Letter

References (11)

1. Tan CK. Incidence of hepatocellular carcinoma after seroclearance is not reduced. Hepatology 2016; doi: 10.1002/hep.28505.
2. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51:1531-1537.
3. Gounder P, Bulkow L, McMahon B. Correction. Hepatology 2015;62:1330.
4. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014;63:1648-1657.
5. Simonetti JB, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Reply. Hepatology 2016; doi: 10.1002/hep.28501.
6. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
7. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:64-70.
8. Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 2015;62:694-701.
9. Jung KS, Kim SU, Song K, Park JY, Kim do Y, Ahn SH, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology 2015;62:1757-1766.
10. Suh B, Park S, Shin DW, Yun JM, Yang HK, Yu SJ, et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology 2015;61:1261-1268.
11. Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015;62:1893-1908.